Comorbidities in primary aldosteronism
- PMID: 20049673
- DOI: 10.1055/s-0029-1243257
Comorbidities in primary aldosteronism
Abstract
Patients presenting with primary aldosteronism experience more cardiovascular events than patients with essential hypertension independent of blood pressure. Therefore, the presence of primary aldosteronism should be detected, not only to determine the cause of hypertension, but also to prevent such complications. This review focuses on human data regarding increased end-organ damage and comorbidities in primary aldosteronism. Special emphasis is put on the effects of aldosterone excess on blood vessels, the heart, the kidney, and the brain. The data reviewed in our article demonstrate that primary aldosteronism is associated with a prevalence of cerebro-, cardiovascular and renal complications that are out of proportion to the blood pressure and benefits substantially from treatment in the long term. In this view, adrenalectomy and aldosterone antagonist treatment seem to be of considerable therapeutic value to control and limit the progression of comorbidities in primary aldosteronism.
Georg Thieme Verlag KG Stuttgart-New York.
Similar articles
-
Cardiovascular outcomes in patients with primary aldosteronism after treatment.Arch Intern Med. 2008 Jan 14;168(1):80-5. doi: 10.1001/archinternmed.2007.33. Arch Intern Med. 2008. PMID: 18195199
-
Tumor size of Conn's adenoma and comorbidities.Horm Metab Res. 2009 Oct;41(10):785-8. doi: 10.1055/s-0029-1224200. Epub 2009 Jun 22. Horm Metab Res. 2009. PMID: 19548184
-
Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism.Horm Metab Res. 2010 Jun;42(6):440-5. doi: 10.1055/s-0029-1246185. Epub 2010 Jan 29. Horm Metab Res. 2010. PMID: 20119883 Review.
-
Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment.J Hypertens. 2007 Jul;25(7):1443-50. doi: 10.1097/HJH.0b013e328126855b. J Hypertens. 2007. PMID: 17563567
-
Primary aldosteronism: cardiovascular, renal and metabolic implications.Trends Endocrinol Metab. 2008 Apr;19(3):88-90. doi: 10.1016/j.tem.2008.01.006. Epub 2008 Mar 7. Trends Endocrinol Metab. 2008. PMID: 18314347 Review.
Cited by
-
Who should be screened for primary aldosteronism? A comprehensive review of current evidence.J Clin Hypertens (Greenwich). 2022 Sep;24(9):1194-1203. doi: 10.1111/jch.14558. J Clin Hypertens (Greenwich). 2022. PMID: 36196469 Free PMC article. Review.
-
Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.Ir J Med Sci. 2014 Jun;183(2):283-91. doi: 10.1007/s11845-013-1007-x. Epub 2013 Aug 30. Ir J Med Sci. 2014. PMID: 23990176 Review.
-
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Endocr Rev. 2024 Jan 4;45(1):125-170. doi: 10.1210/endrev/bnad026. Endocr Rev. 2024. PMID: 37556722 Free PMC article.
-
Physiological Aldosterone Concentrations Are Associated with Alterations of Lipid Metabolism: Observations from the General Population.Int J Endocrinol. 2018 Mar 27;2018:4128174. doi: 10.1155/2018/4128174. eCollection 2018. Int J Endocrinol. 2018. PMID: 29780416 Free PMC article.
-
Proanthocyanidins Maintain Cardiac Ionic Homeostasis in Aldosterone-Induced Hypertension and Heart Failure.Int J Mol Sci. 2021 Sep 4;22(17):9602. doi: 10.3390/ijms22179602. Int J Mol Sci. 2021. PMID: 34502509 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources